African American relapsed/refractory multiple myeloma patients have a progression free survival benefit with selinexor treatment in the STORM study

被引：0
|
作者：
Cole, Craig [1 ]
Opalikhin, Anne [2 ]
McCartney, Matthew [3 ]
Heideman, Caroline [4 ]
Pentapati, Swetha [4 ]
Wang, Ling [5 ]
机构：
[1] Michigan State Univ, Karmanos Canc Inst, E Lansing, MI 48824 USA
[2] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA
[3] Michigan State Univ, Coll Osteopath Med, McLaren Greater Lansing, E Lansing, MI 48824 USA
[4] Michigan State Univ, Karmanos Canc Inst, McLaren Greater Lansing, E Lansing, MI 48824 USA
[5] Michigan State Univ, Coll Human Med, Dept Med, Div Occupat & Environm Med, E Lansing, MI 48824 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-241
引用
收藏
页码：S168 / S169
页数：2
相关论文
共 50 条
  • [41] Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Salcedo, Meghan
    Lendvai, Nikoletta
    Mastey, Donna
    Schlossman, Julia
    Hultcrantz, Malin
    Korde, Neha
    Mailankody, Sham
    Lesokhin, Alexander
    Hassoun, Hani
    Smith, Eric
    Shah, Urvi
    Diab, Victoria
    Werner, Kelly
    Landau, Heather
    Lahoud, Oscar
    Drullinsky, Pamela
    Shah, Gunjan
    Chung, David
    Scordo, Michael
    Giralt, Sergio
    Landgren, Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (03): : 198 - 200
  • [42] Selinexor Combined With Bortezomib, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Who Have Undergone Severe Treatment: A Single-Arm, Multicenter, Prospective Study
    He Song
    Zhong Yi
    Yang Yang
    Zheng Gaofeng
    He, Donghua
    Han, Xiaoyan
    Jiang Songfu
    Shou Lihong
    Qian Honglan
    Zhou Shujuan
    Zhang Liming
    Zhen Cai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S261
  • [43] Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    White, Darrell J.
    Bensinger, William
    Gasparetto, Cristina J.
    Leblanc, Richard
    Venner, Christopher P.
    Lentzsch, Suzanne
    Schiller, Gary J.
    Lipe, Brea
    Del Col, Aldo
    Shah, Jatin J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Kauffman, Michael G.
    Shacham, Sharon
    Bahlis, Nizar
    BLOOD, 2018, 132
  • [44] Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lipe, Brea
    Tuchman, Sascha
    Callander, Natalie Scott
    Lentzsch, Suzanne
    Baljevic, Muhamed
    Rossi, Adriana C.
    Bahlis, Nizar J.
    White, Darell
    Chen, Christine
    Sutherland, Heather J.
    Kotb, Rami
    LeBlanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Bensinger, William
    Sheehan, Heidi
    Ju, Yawen
    Kai, Kazuharu
    Schiller, Gary J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
  • [46] New Long Term Data on Elotuzumab shows a persistent Advantage of progression free Survival in Patients with relapsed or refractory Multiple Myeloma
    Viragh, Eszter
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (1-2)
  • [47] Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials
    Abid, Haisam
    Wu, James F.
    Abid, Muhammad Bilal
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 7 - 10
  • [48] Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials
    Wu, James
    Abid, Haisam
    Abid, Muhammad Bilal
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 159 - 160
  • [49] A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma
    Derman, Benjamin A.
    Chari, Ajai
    Zonder, Jeffrey
    Major, Ajay
    Stefka, Andrew T.
    Jiang, Ken
    Karrison, Theodore
    Jasielec, Jagoda
    Jakubowiak, Andrzej
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 110 (05) : 564 - 570
  • [50] Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma
    Yang, Hongbo
    Roy, Anuja
    Yang, Chelsey
    McDonald, Evangeline
    Krishna, Arun
    Kuriakose, Emil T.
    Globe, Denise
    Siegel, David
    Jagannath, Sundar
    BLOOD, 2015, 126 (23)
12345